NMTC
NASDAQNeuroOne Medical Technologies Corporation
$0.94+0.07 (+8.45%)
NeuroOne Medical Technologies Corporation (NMTC) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for NMTC, including 3 press releases and news items, 1 earnings update and 1 SEC filing. The most recent was published Oct 29, 2026.
Price$0.94-0.76 (-44.90%)
2026-07-302026-10-30
News · 26 weeks26-50%
2026-05-102026-11-01
Mix1590d
- Insider6(40%)
- SEC Filings4(27%)
- Other4(27%)
- Earnings1(7%)
Latest news
25 items- PRNeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation SystemStudy Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on the surgical diagnosis and treatment of neurological disorders, today announced the publication of initial clinical results evaluating its OneRF® Trigeminal Nerve Ablation System in the peer-reviewed journal Pain Management. The article, "OneRF r
- PRNeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research ProgramMajor Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company. The research program is expected to commence in large animals early next year. The
- PRNeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing TechnologyNew NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology. Researchers at Dartmouth College, led by Associate Professor of Engineering Hui Fang, have received a National Institutes of Health (NIH) grant of approximately $1 mil
- SECNeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- PRNeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase OrderPreliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders. NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million,
- PRNeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution AgreementEDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Angeles metropolitan area, expanding commercial access in an important U.S. market and advancing the Company’s strategy to build distribution across key U.S. markets. Trigeminal neuralgia is a debilitating chronic pain condition affecting the trigeminal nerv
- INSIDERChief Business Officer Wambeke David J. bought $66,999 worth of shares (33,333 units at $2.01), increasing direct ownership by 20% to 199,999 units (SEC Form 4)4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERSEC Form 4 filed by Chief Administrative Officer Johns Emily J.4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Volker Christopher4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERSEC Form 4 filed by Market Development Director Christianson Mark4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Mertens Steve4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERSEC Form 4 filed by CEO & President Rosa David A4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- SECNeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECSEC Form 10-Q filed by NeuroOne Medical Technologies Corporation10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECNeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies CorporationSCHEDULE 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
- INSIDERNew insider Pratt Brian claimed ownership of 1,085,934 shares (SEC Form 3)3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- INSIDERMarket Development Director Christianson Mark sold $31,773 worth of shares (10,000 units at $3.18), decreasing direct ownership by 33% to 20,692 units (SEC Form 4)4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
- SECSEC Form 424B5 filed by NeuroOne Medical Technologies Corporation424B5 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECNeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by NeuroOne Medical Technologies Corporation10-Q/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECSEC Form SD filed by NeuroOne Medical Technologies CorporationSD - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECSEC Form SD filed by NeuroOne Medical Technologies CorporationSD - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECNeuroOne Medical Technologies Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
- SECSEC Form 10-Q filed by NeuroOne Medical Technologies Corporation10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
NMTC FAQ
7 questionsWhat does NeuroOne Medical Technologies Corporation do?
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a...What is the latest news on NMTC?
In the last 30 days Quantisnow tracked 5 wire items for NMTC: 3 press releases and news items, 1 earnings update and 1 SEC filing. The most recent was published on October 29, 2026.Where does NMTC stock trade?
NeuroOne Medical Technologies Corporation (NMTC) is listed on NASDAQ.What sector and industry is NMTC in?
NeuroOne Medical Technologies Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about NMTC?
Across the last 4 analyst actions on NeuroOne Medical Technologies Corporation, there were 0 upgrades and 1 downgrade. The most recent action was from Ladenburg Thalmann: Buy with a $1.45 price target on 2025-05-05. Recent price targets range from $1.45 to $6.00.What companies are similar to NMTC?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare NMTC side-by-side with any of them on Quantisnow.How can I track NMTC on Quantisnow?
Quantisnow aggregates NeuroOne Medical Technologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NMTC to receive live email and push alerts on every new disclosure.